Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • ATVB Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Cover Art Award
    • ATVB Early Career Award
    • ATVB in Focus
    • Recent Brief Reviews of ATVB
    • Lecture Series
    • Collections
    • Recent Highlights of ATVB
    • Commentaries
    • Browse Abstracts
    • Insight into ATVB Authors
  • Resources
    • Instructions for Authors
    • Online Submission/Peer Review Site
    • Council on ATVB
    • Permissions and Rights Q&A
    • AHA Guidelines and Statements
    • Customer Service and Ordering Information
    • Author Reprints
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • LinkedIn
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Arteriosclerosis, Thrombosis, and Vascular Biology

  • My alerts
  • Sign In
  • Join

  • Facebook
  • LinkedIn
  • Twitter
  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • ATVB Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Cover Art Award
    • ATVB Early Career Award
    • ATVB in Focus
    • Recent Brief Reviews of ATVB
    • Lecture Series
    • Collections
    • Recent Highlights of ATVB
    • Commentaries
    • Browse Abstracts
    • Insight into ATVB Authors
  • Resources
    • Instructions for Authors
    • Online Submission/Peer Review Site
    • Council on ATVB
    • Permissions and Rights Q&A
    • AHA Guidelines and Statements
    • Customer Service and Ordering Information
    • Author Reprints
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Integrative Physiology/Experimental Medicine

Kruppel-Like Factor 2 Regulates Endothelial Barrier Function

Zhiyong Lin, Viswanath Natesan, Hong Shi, Fei Dong, Daiji Kawanami, Ganapati H. Mahabeleshwar, G. Brandon Atkins, Lalitha Nayak, Yingjie Cui, James H. Finigan, Mukesh K. Jain
Download PDF
https://doi.org/10.1161/ATVBAHA.110.211474
Arteriosclerosis, Thrombosis, and Vascular Biology. 2010;30:1952-1959
Originally published September 15, 2010
Zhiyong Lin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Viswanath Natesan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hong Shi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fei Dong
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daiji Kawanami
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ganapati H. Mahabeleshwar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Brandon Atkins
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lalitha Nayak
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yingjie Cui
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James H. Finigan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mukesh K. Jain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Supplemental Materials
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Supplemental Materials
  • Info & Metrics
  • eLetters
Loading

Abstract

Objective—A central function of the endothelium is to serve as a selective barrier that regulates fluid and solute exchange. Although perturbation of barrier function can contribute to numerous disease states, our understanding of the molecular mechanisms regulating this aspect of endothelial biology remains incompletely understood. Accumulating evidence implicates the Kruppel-like factor 2 (KLF2) as a key regulator of endothelial function. However, its role in vascular barrier function is unknown.

Methods and Results—To assess the role of KLF2 in vascular barrier function in vivo, we measured the leakage of Evans blue dye into interstitial tissues of the mouse ear after treatment with mustard oil. By comparison with KLF2+/+ mice, KLF2+/− mice exhibited a significantly higher degree of vascular leak. In accordance with our in vivo observation, adenoviral overexpression of KLF2 in human umbilical vein endothelial cells strongly attenuated the increase of endothelial leakage by thrombin and H2O2 as measured by fluorescein isothiocyanate dextrans (FITC-dextran) passage. Conversely, KLF2 deficiency in human umbilical vein endothelial cells and primary endothelial cells derived from KLF2+/− mice exhibited a marked increase in thrombin and H2O2-induced permeability. Mechanistically, our studies indicate that KLF2 confers barrier-protection via differential effects on the expression of key junction protein occludin and modification of a signaling molecule (myosin light chain) that regulate endothelial barrier integrity.

Conclusion—These observations identify KLF2 as a novel transcriptional regulator of vascular barrier function.

  • endothelium
  • Kruppel-like factor 2
  • barrier function

The endothelium forms the inner lining of all blood vessels and regulates vascular barrier function, blood coagulation, and homing of immune cells to specific sites of the body.1 Under normal physiological conditions, the endothelial monolayer serves as a barrier that maintains the integrity of the blood-fluid compartment and allows for the selective passage of liquid, solutes, and leukocytes.1 In contrast, under pathophysiologic conditions, the integrity of the endothelium can be perturbed, resulting in leakage of fluids into the extravascular space.

Movement of fluid and solutes through the endothelium occurs either across cells (transcellular) or between cells (paracellular).2 Although the former mechanism contributes to basal barrier function of the endothelium, paracellular flux has received increasing attention for its pathophysiologic importance in disease states, such as ischemia-reperfusion injury, diabetic vasculopathy, and acute lung injury.2 Propermeability factors, such as thrombin and hydrogen peroxide or inflammatory stimuli (eg, lipopolysaccharide or tumor necrosis factor α), promote paracellular vascular leak by 2 predominant mechanisms.3,4–6 One mechanism is by the disruption of the cell-cell junctions between endothelial cells (ECs), which involves the regulation of adhesive proteins that reside at the junctions between cells, termed tight junctions (TJs) and adherens junctions (AJs).7–9 The other mechanism is cytoskeletal contraction, leading to widened intercellular space, which involves activation of signaling molecules that converge on myosin light chain (MLC) kinase.10–12 The resulting phosphorylation of MLC induces actin-myosin-mediated EC contraction, thereby pulling neighboring ECs apart from each other.12 Collectively, these mechanisms enhance paracellular leak and thereby contribute to the pathology observed in disease states. Despite considerable effort, our understanding of the molecular mechanisms regulating endothelial barrier function remains incompletely understood. As such, the identification of factors that regulate endothelial barrier function is of considerable scientific interest.

Kruppel-like factors (KLFs) are a subclass of the zinc finger family of DNA-binding transcription factors.13 Accumulating evidence from our group and others has led to the appreciation that members of this gene family critically regulate endothelial function and vascular homeostasis.14,15 Among this gene family, KLF2 has emerged as particularly important in endothelial biology. KLF2 is a shear stress-induced factor that confers antiinflammatory and antithrombotic properties to the vascular EC.15–21 However, despite the acknowledged importance of the endothelium in determining vascular barrier function, studies assessing the role of KLF2 (or any other member of this gene family) have not been reported. Here, we provide in vitro and in vivo evidence implicating KLF2 as an essential regulator of endothelial barrier integrity.

Materials and Methods

An expanded Materials and Methods section can be found in the supplemental materials, available online at http://atvb.ahajournals.org.

Measurement of Endothelial Leakage

A commercially available kit (Millipore, Temecula, Calif) was used to measure EC monolayer leakage to high molecular weight proteins utilizing 2,000-kDa FITC-dextran based on the Transwell model. Briefly, a Transwell insert was coated with collagen for 1 h at room temperature, and ECs were then seeded at a density of 2×105/well in a final volume of 400 μl endothelial growth medium-2 with supplements. The inserts were placed into 24-well plates containing 500 μl medium overnight. To measure agonist-induced EC leakage, 200 μl FITC-dextran was added into the insert and incubated for 2 h. The insert was then removed and 50 μl medium was collected from the bottom chamber. The fluorescence density of samples was analyzed on a Microplate Fluorometer at excitation and emission wavelengths of 485 nm and 530 nm respectively. In experiments where adenoviruses were used, the control group was human umbilical vein endothelial cells (HUVECs) infected with adenovirus encoding green fluorescent protein (Ad-GFP); in leakage assays involving siRNA transfection, the control group was HUVECs transfected with non-specific siRNA; in experiments where murine primary ECs were used, ECs from KLF2+/+ mice without treatment were set as control.

Vascular Barrier Function Assay

All animals were handled according to Institutional Animal Care and Use Committee protocol (no. 2009-0108) approved by the Institutional Animal Care and Use Committee at Case Western Reserve University, which is certified by the American Association of Accreditation for Laboratory Animal Care. Evans blue dye (EBD) (30 mg/kg in 100 μL normal saline) was injected into the jugular vein of 7- to 8-week-old male mice. In some experiments, after 1 minute, mustard oil diluted to 5% in mineral oil was applied to the dorsal and ventral surfaces of the ear with a cotton swab; photographs were taken 15 minutes after EBD injection. After the mice were euthanized by CO2 inhalation, ears were removed, blotted dry, and weighed. The EBD was extracted from the ears with 1 mL of formamide overnight at 55°C and measured spectrophotometrically at 620 nm. The amount of EBD in each sample was calculated according to a standard curve generated from known amounts of EBD and expressed as μg of dye/mg of ear tissue.22

Isolation of Primary Endothelial Cells from Mice

KLF2+/− mice (generously provided by J. Leiden) were generated as previously described.23,24 Murine lungs were obtained from 4- to 6-week-old KLF2+/+ and KLF2+/− mice on CD1 background. Murine ECs from these lungs were isolated through selection with intercellular adhesion molecule-2 antibody (BD Biosciences) bound to Dynabeads (Invitrogen). In brief, murine lungs were minced and digested with collagenase for 30 minutes, after which cells were treated with red blood cell lysis buffer, and the remaining cells were plated on 0.1% gelatin coated plates. When the plate becomes confluent, ECs were selected using intercellular adhesion molecule-2 and then replated on collagen-coated plates for further use. Purity of lung microvascular EC cultures was assessed by immunohistochemistry for the EC specific marker CD31 and was found to be >80%.

Results

Hemizygous Deficiency of KLF2 Augments Vascular Leakage

As a first step toward understanding the role of KLF2 in vascular barrier function, we performed in vivo assays to assess vascular leak in KLF2 heterozygous mice. These mice were used because both systemic and endothelial-specific deletion of KLF2 results in embryonic death.24,25 EBD was injected IV into the jugular vein followed by treatment of the ear with mustard oil, a local inflammatory stimuli that induces inflammation and plasma leakage.22,26 As expected, 15 minutes following application of mustard oil, a blue coloration developed in the ears of wild-type mice (Figure 1A). However, the EBD staining was much more intense in the KLF2 heterozygous mice. Consistent with this observation, quantitative analysis of extravasation of dye from the vasculature in ears revealed a significantly greater increase of EBD in the heterozygous mice compared with the wild-type mice (53.4±2.68 μg/mg in KLF2+/+ versus 72.36±4.71 μg/mg in KLF2+/−, P=0.042) (Figure 1B). These data indicate that partial deficiency of KLF2 enhanced vascular leakage in response to an inflammatory stimuli.

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 1. Hemizygous deficiency of KLF2 shows increased vascular permeability in response to mustard oil. A, Seven- to 8-week-old male wild-type and KLF2 heterozygous mice were used for this experiment. Evans blue dye (EBD) was injected into the mice through internal jugular vein. Mustard oil was applied 1 minute later to the mice ear, photographs were taken after 15 minutes; then the mice were euthanized and ear lobes harvested. Representative pictures are shown. B, The ears were later cut into small pieces and the dye extracted using 1 mL of formamide, the EBD amount in each sample was quantified by spectrophotometer at a wavelength of 620 nm and normalized to ear weight. In KLF2 heterozygous mice, the amount of dye extravasated was statistically significant higher when compared with that of wild type (n=9, P<0.05).

KLF2 Overexpression Prevents Endothelial Leakage by Diverse Stimuli

As discussed above, diverse inflammatory stimuli can induce intercellular gap formation by disrupting cell to cell adhesion proteins or by promoting cytoskeletal changes, ultimately resulting in parcellular leak and an increase in endothelial leakage.7–12 In order to directly assess the role of KLF2 in regulating endothelial barrier function, we performed gain-of-function studies. A monolayer of HUVEC was infected with control (Ad-GFP) or KLF2 (Ad-KLF2) virus for 48 hours, challenged with thrombin (1 U/mL), and then assessed for barrier function using 3 separate assessments: intercellular gap formation, FITC-dextran passage, and change in transendothelial electric resistance. First, treatment with thrombin resulted in a dramatic intercellular gap formation in control virus-treated HUVECs (Figure 2A). In contrast, HUVECs infected with KLF2 adenovirus were essentially resistant to intercellular gap formation. Next, we performed FITC-dextran passage leakage assays using a transwell system. Stimulation of HUVECs with thrombin caused a significant increase in leakage as measured by the passage of FITC-dextran through the HUVEC monolayer (Figure 2B). However, in the presence of KLF2 overexpression, the passage of FITC-dextran was markedly reduced. Similar findings were observed following treatment of HUVECs with hydrogen peroxide (Figure 2C) and histamine (data not shown). Finally, we analyzed transendothelial electric resistance change as a third assay for barrier integrity. Consistent with what we observed using the other 2 methods, KLF2 significantly attenuated thrombin and histamine-mediated reduction in transendothelial electric resistance (supplemental Figure IA and IB). Collectively, these observations strongly implicate KLF2 as an important barrier protective factor in ECs.

Figure2
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 2. Overexpression of KLF2 decreases endothelial leakage. A, KLF2 overexpressed cells significantly attenuates thrombin-mediated interendothelial gap formation when compared with Ad-GFP-infected cells. Confluent HUVECs were infected with control (Ad-GFP) or KLF2 adenovirus for 48 hours, exposed to thrombin (1 U/mL for 15 minutes), and interendothelial gap formation assessed by actin staining. Percentage of exposed areas was quantified by National Institutes of Health ImageJ software. The control group (Ad-GFP with thrombin) was normalized to 100%. A representative of 3 independent experiments is shown. Scale bar, 50 μm. B, KLF2 decreases endothelial leakage when HUVECs were challenged with thrombin (1 U/mL). HUVECs were infected as in A, treated with thrombin (1 U/mL), and leakage assay was performed to measure FITC-dextran passage. N=6, P<0.01. C, KLF2 decreases endothelial leakage when HUVECs were treated with 200 μmol/L of tert-butyl hydrogen peroxide. N=6, P<0.01.

KLF2 Deficiency Augments Endothelial Leakage Increase

To further substantiate KLF2’s role in regulating endothelial barrier function, we carried out loss-of-function studies. First, we acutely knocked down KLF2 expression in HUVECs by siRNA-mediated silencing and examined intercellular gap formation. HUVECs were transfected with NS or specific siRNA targeting for human KLF2 (siKLF2), treated with thrombin, and intercellular gap formation was assessed. Consistent with the overexpression studies above, on stimulation with thrombin, KLF2 deficiency in HUVECs led to an enhancement of gap formation (Figure 3A). Next, we carried out endothelial leakage assays using HUVECs deficient in KLF2 as well as primary lung ECs from KLF2 heterozygous mice. HUVECs were transfected with siKLF2 or NS siRNA for 48 hours, replated on the transwell, challenged with thrombin (or hydrogen peroxide), and assessed for FITC-dextran passage. By comparison with the NS group, knockdown of KLF2 augmented both basal and thrombin (or hydrogen peroxide)-mediated increase of leakage (Figure 3B and 3C). We also examined the FITC-dextran passage using primary mouse lung microvascular ECs. By comparison with primary lung ECs from KLF2+/+ mice, KLF2+/− ECs exhibited enhanced leak in response to thrombin (Figure 3D). Taken together, the results from the loss of function studies provided complementary evidence supporting the role of KLF2 as an endothelial barrier protector.

Figure3
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 3. KLF2 deficiency increases endothelial leakage. A, KLF2 deficiency in HUVEC lead to an enhancement of interendothelial gap formation response to thrombin treatment. HUVECs were transfected with control siRNA and KLF2 siRNA; 5 days after transfection, cells were treated with thrombin (1 U/mL) for gap formation assessment by actin staining. Percentage of exposed areas was quantified by National Institutes of Health ImageJ software. The control group (NS with thrombin) was normalized to 100%. A representative of 3 independent experiments is shown. Scale bar, 50 μm. B, Deficiency of KLF2 lead to increased endothelial leakage in response to thrombin. HUVECs were transfected with control siRNA and KLF2 siRNA for 2 days, then cells were replated onto transwell; permeability analysis was performed following treatment with thrombin. N=6, P<0.01. C, KLF2 deficiency leads to increased endothelial leakage in response to hydrogen peroxide. HUVECs were transfected as above and treated with hydrogen peroxide (200 μmol/L) followed by permeability assay. N=6, P<0.01. D, Partial deficiency of KLF2 in primary ECs lead to a significant increase of endothelial leakage when treated with thrombin. Confluent lung microvascular ECs from KLF2+/+ and KLF2+/− mice were treated with thrombin, then permeability assay performed. N=6, P<0.01.

KLF2 Regulates Key Tight Junction Protein Occludin in Endothelial Cells

The observations from KLF2 overexpression and deficiency studies discussed above suggest that KLF2 regulates gap formation between ECs. As noted earlier, intercellular junctions are composed of 2 main types of proteins: TJs and AJs. To assess for effects on specific intercellular junction proteins, we performed gain-of-function and loss-of-function studies. Knockdown of KLF2 reduced 1 key TJ protein, occludin (Figure 4A). However, no significant effect was observed on zona-occludens-1 and zona-occludens-2 (data not shown). A similar reduction was seen in primary microvascular ECs from KLF2+/− mice (Figure 4B). However, no significant effect was observed on the adherens proteins vascular endothelial-cadherin and its associated actin-binding molecules α-, β-, and, γ-catenin (data not shown). To determine whether occludin is a direct target of KLF2, we performed overexpression studies. Forced expression of KLF2 potently induced the expression of occludin promoter (supplemental Figure IIA), mRNA (supplemental Figure IIB), and protein expression (Figure 4C). These results demonstrate that KLF2 is able to regulate 1 key TJ protein occludin in ECs.

Figure4
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 4. KLF2 increases the expression of tight junction protein occludin. (A) siRNA-mediated KLF2 knockdown reduces occludin. HUVEC were transfected with non-specific siRNA and KLF2 siRNA for 48 hrs, and protein harvested for Western analysis. Representative blots of three independent experiments are shown. (B) Partial KLF2 deficiency in primary ECs results in decrease of occludin expression. Primary microvascular ECs were isolated from KLF2+/+ and KLF2+/− mice, extracted total protein were subjected to western blot. WT = KLF2+/+, Het = KLF2+/−. (C) Overexpression of KLF2 increases occludin expression. HUVEC were infected with Ad-GFP and KLF2 adenovirus for 24 hrs. Cells were treated with thrombin (1U/ml) for 30 minutes and proteins extracted for western blot analysis. Representative blots of three independent experiments are shown. Exo-KLF2 indicates Exogenous KLF2.

KLF2 Inhibits Phosphorylation of MLC in Endothelial Cells

Most paracellular leak pathways induce actomyosin-based cell contractility, which augments intercellular gaps, leading to increased leakage.12 Importantly, activation of paracellular leak by diverse stimuli all result in the phosphorylation of MLC, a key event in cell contraction.11,27 In light of the observation that KLF2 prevents cellular contraction and gap formation following thrombin stimulation (Figure 2A), we hypothesized that KLF2 may alter MLC phosphorylation. HUVECs were infected with control (Ad-GFP) and Ad-KLF2 for 48 hours, stimulated with thrombin (1 U/mL), and cell lysates assessed for phosphorylated MLC (serine 19 and threonine 18).11 As expected, following treatment with thrombin, a strong increase in MLC phosphorylation was observed (Figure 5A). Importantly, sustained expression of KLF2 strongly reduced the level of phospho-MLC (Figure 5A). A similar effect was observed with hydrogen peroxide treatment (Figure 5B). However, the expression of total MLC was not significantly altered by KLF2. We next investigated the spatially defined effects of KLF2 on MLC phosphorylation as assessed by phosphorylated myosin light chain staining. Consistent with the Western blot analysis data, KLF2 overexpression markedly reduced phospho-MLC in ECs (Figure 5C). Conversely, knockdown of KLF2 in HUVECs resulted in a hyperphosphorylation of MLC following thrombin treatment (Figure 5D). Concordant effects were seen in primary ECs derived from wild-type and KLF2 heterozygous mice (Figure 5E). Collectively, these studies clearly indicate that KLF2 regulates MLC phosphorylation.

Figure5
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 5. KLF2 inhibits phosphorylation of MLC in response to agonists. A, HUVECs were infected with Ad-GFP and KLF2 adenovirus for 24 hrs, cells were then treated with thrombin (1U/ml) for 30 minutes, and proteins were then extracted. Western blot analysis reveals attenuation of MLC phosphorylation in KLF2 overexpressed cells. Representative blot of three independent experiments is shown. Exo-KLF2 indicates Exogenous KLF2. B, HUVECs were infected as above, followed by treatment with hydrogen peroxide for 30 and 60 minute, and total proteins were isolated and subjected to Western blot analysis. Representative blots of 3 independent experiments are shown. C, HUVECs infected with Ad-GFP and KLF2 adenovirus for 24 hours were treated with thrombin (1 U/mL) for 15 minutes, then immunostaining with phospho-MLC antibody was performed. Representative pictures of 3 independent experiments are shown. Scale bar, 50 μm. D, HUVEC were transfected with NS siRNA and siKLF2 using siPortAmine. After 48 hours, the cells were treated with thrombin (1 U/mL) for 1 minute and total protein harvested using radio-immunoprecipitation assay buffer. Western blot analysis revealed increased phosphorylation of MLC in siKLF2-transfected cells when compared with NS siRNA-transfected cells. E, Primary lung microvascular ECs were isolated from KLF2+/+ and KLF2+/− mice, they were then treated with mouse thrombin for 1 minute, and proteins were extracted and Western blot analysis performed. A significant increase of MLC phosphorylation was observed in KLF2+/− ECs than that of KLF2+/+ ECs. A representative blot of 3 independent experiments is shown. P indicates phosphorylated; Exo, exogenous; DAPI, 4′,6-diamidino-2-phenylindole.

Discussion

This study is the first to implicate KLF2 as an essential regulator of vascular barrier function. This primary conclusion is supported by several key observations. First, hemizygous deficiency of KLF2 enhances vascular leak in response to an inflammatory stimulus. Second, in vitro gain-of-function and loss-of-function studies indicate that KLF2 regulates endothelial barrier function. Finally, mechanistic studies reveal that KLF2 differentially regulates expression of specific junction molecules and signaling molecules that mediate intercellular contact and cellular contraction. These findings build on previous observations and expand our understanding of KLF2’s role in vascular homeostasis.

Mediators such as thrombin, H2O2, and histamine activate very distinct mechanisms to exert their effects on endothelial barrier function.3,5,28–31 The fact that KLF2 was able to ameliorate barrier function induced by such diverse stimuli was an important initial observation and suggested that its actions likely occur at some common convergence point. This line of reasoning led us to evaluate the 2 hallmark downstream events of paracellular leak: cellular contraction and interendothelial junctions. Indeed, our studies identify critical and specific roles for KLF2 in both processes.

A common downstream convergence point for diverse stimuli that induce endothelial barrier dysfunction (eg, thrombin, histamine, and H2O2) is MLC phosphorylation.3,28 This phosphorylation event leads to actin-myosin cross-bridge cycling, cellular contraction, and disruption of interendothelial junctions.12,27,32 Our studies indicate that KLF2 inhibits MLC phosphorylation (Figure 5), an effect consistent with the observation that KLF2 prevents cell rounding and contraction (Figures 2 and 3⇑). Of note, our observations regarding the effect of KLF2 on MLC phosphorylation is not unique to thrombin, because similar results were obtained when cells were challenged with histamine or hydrogen peroxide. The fact that KLF2 can block MLC phosphorylation and leakage in response to numerous stimuli renders it an appealing therapeutic target given that multiple mediators contribute to vascular leak in most disease processes. We note that the precise molecular basis for how KLF2 alters MLC phosphorylation remains incompletely understood. MLC can be phosphorylated by the endothelial form of MLC kinase.11 This phosphorylation event can be further augmented by RhoA through its downstream effector Rho kinase.33 Finally, KLF2 may alter expression and/or activity of MLC phosphatase. Thus, additional studies are clearly needed to pinpoint the precise basis of KLF2 action.

Two major structures (TJs and AJs) are critical in maintaining the endothelial barrier.1,2,34 Our results indicate that KLF2 selectively affects TJs, an intriguing finding, because in contrast to AJs, our understanding of mechanisms regulating TJs is far less understood.34 Endothelial TJs proteins, such as occludin, form homotypic interactions with neighboring cells.35,36 Occludin also requires coexpression of junctional proteins zona-occludens-1 for cell surface expression and linkage to cortical actin.9 Our findings suggest that KLF2, by inducing the expression of occludin, may help coordinate TJ formation. These observations are likely to be important for specific vascular beds, such as the blood-brain barrier and retinal microvasculature, where TJs are abundant.37 We recognize that the role of occludin specifically and TJs in general has not been well established to participate significantly in microvascular barrier regulation. However, our data in primary murine microvascular cells (Figures 3D and 4⇑B) and the work of others35,38–40 demonstrate that occludin is present in microvascular ECs and suggest that changes in occludin mass are associated with alterations in barrier function. Therefore, our data suggest that occludin might be important in the KLF2 effect on barrier function. Finally, although we did not observe significant effects on AJs, it should be noted that inhibition of actin-myosin cycling via effects on MLC phosphorylation indirectly helps maintain these junctions. As such, KLF2 effects on leakage likely result from direct and indirect effects on both the actomyosin complex and its intimate interaction with the interendothelial junction molecules.

There are several important limitations in our study. First, we have focused largely on the paracellular pathway of endothelial barrier function. This is principally because the preponderance of evidence suggests that paracellular leak is likely the dominant mechanism operative in most pathophysiologic states.1 However, we cannot exclude the possibility that KLF2’s effect may also be mediated, in part, via the transcellular pathway, which will be an interesting topic for future investigations. Second, because endothelial-specific deletion of KLF2 results in embryonic death,23–25 our in vivo barrier function studies were performed in KLF2+/− mice. Although our in vitro studies in isolated KLF2+/− cells strongly support a critical role for KLF2 in the endothelium, one cannot exclude the possibility that other cell types (eg, inflammatory cells) may contribute to the phenotype. Third, we note that several additional members of the KLF family are also expressed in ECs.14 Among these, the work of Hamik et al41 suggests that KLF4 may be particularly important in regulating key aspects of endothelial gene expression and function. Interestingly, KLF4 has been shown to regulate epithelial barrier function,42–44 and thus future studies comparing and contrasting KLF2 and KLF4 function in endothelial barrier function are requisite.

Studies of the past decade strongly implicate KLF2 as a molecular switch that imparts an antiinflammatory, antithrombotic, and antiproliferative effect on ECs. Remarkably, these conclusions were derived largely (if not exclusively) on studies in cultured EC lines. However, recent reports have begun to validate many of the predicted effects of KLF2 in vivo. Importantly, Atkins et al45 recently reported that hemizygous deficiency of KLF2 augments experimental atherosclerosis. The observations in this study are the first to provide evidence that KLF2 plays an essential role in maintaining endothelial barrier integrity. These observations build on previous work and further substantiate the contention that KLF2 is an essential regulator of EC biology and vascular homeostasis. Finally, the increasing appreciation that KLF2 levels are induced by diverse pharmacological agents (eg, statins, resveratrol, and proteasome inhibitors) heightens enthusiasm that targeting of this factor may confer therapeutic benefit.46–48

Acknowledgments

Sources of Funding

This work was supported by National Institutes of Health Grants HL72952, HL75427, HL76754, HL086548, HL084154, and P01 HL48743 (to M.K.J.), HL087595 (to Z.L.), HL088740 (to G.B.A.), HL097023 (to G.H.M), and HL086668 (to J.H.F.); a Robert Wood Johnson/Harold Amos Medical Faculty Development grant (G.B.A.); and American Heart Association Grants 0635579T (to Z.L.) and 0725297B (to D.K.).

Disclosures

None.

Footnotes

  • Z.L. and V.N. contributed equally to this work.

  • Received on: March 30, 2010; final version accepted on: July 12, 2010.

References

  1. ↵
    Mehta D, Malik AB. Signaling mechanisms regulating endothelial permeability. Physiol Rev. 2006; 86: 279–367.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Kumar P, Shen Q, Pivetti CD, Lee ES, Wu MH, Yuan SY. Molecular mechanisms of endothelial hyperpermeability: implications in inflammation. Expert Rev Mol Med. 2009; 11: e19.
    OpenUrlCrossRefPubMed
  3. ↵
    van Nieuw Amerongen GP, Draijer R, Vermeer MA, van Hinsbergh VW. Transient and prolonged increase in endothelial permeability induced by histamine and thrombin: role of protein kinases, calcium, and RhoA. Circ Res. 1998; 83: 1115–1123.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Siflinger-Birnboim A, Lum H, Del Vecchio PJ, Malik AB. Involvement of Ca2+ in the H2O2-induced increase in endothelial permeability. Am J Physiol. 1996; 270: L973–L978.
    OpenUrlPubMed
  5. ↵
    Moy AB, Blackwell K, Kamath A. Differential effects of histamine and thrombin on endothelial barrier function through actin-myosin tension. Am J Physiol Heart Circ Physiol. 2002; 282: H21–H29.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    McKenzie JA, Ridley AJ. Roles of Rho/ROCK and MLCK in TNF-α-induced changes in endothelial morphology and permeability. J Cell Physiol. 2007; 213: 221–228.
    OpenUrlCrossRefPubMed
  7. ↵
    Lum H, Malik AB. Regulation of vascular endothelial barrier function. Am J Physiol. 1994; 267: L223–L241.
    OpenUrlPubMed
  8. ↵
    Wojciak-Stothard B, Ridley AJ. Rho GTPases and the regulation of endothelial permeability. Vascul Pharmacol. 2002; 39: 187–199.
    OpenUrlCrossRefPubMed
  9. ↵
    Bazzoni G, Dejana E. Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. Physiol Rev. 2004; 84: 869–901.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Morel NM, Petruzzo PP, Hechtman HB, Shepro D. Inflammatory agonists that increase microvascular permeability in vivo stimulate cultured pulmonary microvessel endothelial cell contraction. Inflammation. 1990; 14: 571–583.
    OpenUrlCrossRefPubMed
  11. ↵
    Goeckeler ZM, Wysolmerski RB. Myosin light chain kinase-regulated endothelial cell contraction: the relationship between isometric tension, actin polymerization, and myosin phosphorylation. J Cell Biol. 1995; 130: 613–627.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Moy AB, Van Engelenhoven J, Bodmer J, Kamath J, Keese C, Giaever I, Shasby S, Shasby DM. Histamine and thrombin modulate endothelial focal adhesion through centripetal and centrifugal forces. J Clin Invest. 1996; 97: 1020–1027.
    OpenUrlCrossRefPubMed
  13. ↵
    Bieker JJ. Kruppel-like factors: three fingers in many pies. J Biol Chem. 2001; 276: 34355–34358.
    OpenUrlFREE Full Text
  14. ↵
    Feinberg MW, Lin Z, Fisch S, Jain MK. An emerging role for Kruppel-like factors in vascular biology. Trends Cardiovasc Med. 2004; 14: 241–246.
    OpenUrlCrossRefPubMed
  15. ↵
    Atkins GB, Jain MK. Role of Kruppel-like transcription factors in endothelial biology. Circ Res. 2007; 100: 1686–1695.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    SenBanerjee S, Lin Z, Atkins GB, Greif DM, Rao RM, Kumar A, Feinberg MW, Chen Z, Simon DI, Luscinskas FW, Michel TM, Gimbrone MA Jr, Garcia-Cardena G, Jain MK. KLF2 Is a novel transcriptional regulator of endothelial proinflammatory activation. J Exp Med. 2004; 199: 1305–1315.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Lin Z, Kumar A, SenBanerjee S, Staniszewski K, Parmar K, Vaughan DE, Gimbrone MA Jr, Balasubramanian V, Garcia-Cardena G, Jain MK. Kruppel-like factor 2 (KLF2) regulates endothelial thrombotic function. Circ Res. 2005; 96: e48–e57.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Parmar KM, Larman HB, Dai G, Zhang Y, Wang ET, Moorthy SN, Kratz JR, Lin Z, Jain MK, Gimbrone MA Jr, Garcia-Cardena G. Integration of flow-dependent endothelial phenotypes by Kruppel-like factor 2. J Clin Invest. 2006; 116: 49–58.
    OpenUrlCrossRefPubMed
  19. ↵
    Dekker RJ, Boon RA, Rondaij MG, Kragt A, Volger OL, Elderkamp YW, Meijers JC, Voorberg J, Pannekoek H, Horrevoets AJ. KLF2 provokes a gene expression pattern that establishes functional quiescent differentiation of the endothelium. Blood. 2006; 107: 4354–4363.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Dekker RJ, van Soest S, Fontijn RD, Salamanca S, de Groot PG, VanBavel E, Pannekoek H, Horrevoets AJ. Prolonged fluid shear stress induces a distinct set of endothelial cell genes, most specifically lung Kruppel-like factor (KLF2). Blood. 2002; 100: 1689–1698.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Dekker RJ, van Thienen JV, Rohlena J, de Jager SC, Elderkamp YW, Seppen J, de Vries CJ, Biessen EA, van Berkel TJ, Pannekoek H, Horrevoets AJ. Endothelial KLF2 links local arterial shear stress levels to the expression of vascular tone-regulating genes. Am J Pathol. 2005; 167: 609–618.
    OpenUrlCrossRefPubMed
  22. ↵
    Han ED, MacFarlane RC, Mulligan AN, Scafidi J, Davis AE III. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest. 2002; 109: 1057–1063.
    OpenUrlCrossRefPubMed
  23. ↵
    Kuo CT, Veselits ML, Barton KP, Lu MM, Clendenin C, Leiden JM. The LKLF transcription factor is required for normal tunica media formation and blood vessel stabilization during murine embryogenesis. Genes Dev. 1997; 11: 2996–3006.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Kuo CT, Veselits ML, Leiden JM. LKLF: a transcriptional regulator of single-positive T cell quiescence and survival. Science. 1997; 277: 1986–1990.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    Lee JS, Yu Q, Shin JT, Sebzda E, Bertozzi C, Chen M, Mericko P, Stadtfeld M, Zhou D, Cheng L, Graf T, MacRae CA, Lepore JJ, Lo CW, Kahn ML. Klf2 is an essential regulator of vascular hemodynamic forces in vivo. Dev Cell. 2006; 11: 845–857.
    OpenUrlCrossRefPubMed
  26. ↵
    Elson DA, Thurston G, Huang LE, Ginzinger DG, McDonald DM, Johnson RS, Arbeit JM. Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1α. Genes Dev. 2001; 15: 2520–2532.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Dudek SM, Garcia JG. Cytoskeletal regulation of pulmonary vascular permeability. J Appl Physiol. 2001; 91: 1487–1500.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    Rivero-Vilches FJ, de Frutos S, Saura M, Rodriguez-Puyol D, Rodriguez-Puyol M. Differential relaxing responses to particulate or soluble guanylyl cyclase activation on endothelial cells: a mechanism dependent on PKG-I α activation by NO/cGMP. Am J Physiol Cell Physiol. 2003; 285: C891–C898.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    Grand RJ, Turnell AS, Grabham PW. Cellular consequences of thrombin-receptor activation. Biochem J. 1996; 313 (pt 2): 353–368.
    OpenUrlFREE Full Text
  30. ↵
    Kevil CG, Oshima T, Alexander B, Coe LL, Alexander JS. H(2)O(2)-mediated permeability: role of MAPK and occludin. Am J Physiol Cell Physiol. 2000; 279: C21–C30.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    Clough GF, Bennett AR, Church MK. Effects of H1 antagonists on the cutaneous vascular response to histamine and bradykinin: a study using scanning laser Doppler imaging. Br J Dermatol. 1998; 138: 806–814.
    OpenUrlCrossRefPubMed
  32. ↵
    Tiruppathi C, Minshall RD, Paria BC, Vogel SM, Malik AB. Role of Ca2+ signaling in the regulation of endothelial permeability. Vascul Pharmacol. 2002; 39: 173–185.
    OpenUrlCrossRefPubMed
  33. ↵
    Noda M, Yasuda-Fukazawa C, Moriishi K, Kato T, Okuda T, Kurokawa K, Takuwa Y. Involvement of rho in GTP γ S-induced enhancement of phosphorylation of 20 kDa myosin light chain in vascular smooth muscle cells: inhibition of phosphatase activity. FEBS Lett. 1995; 367: 246–250.
    OpenUrlCrossRefPubMed
  34. ↵
    Vandenbroucke E, Mehta D, Minshall R, Malik AB. Regulation of endothelial junctional permeability. Ann N Y Acad Sci. 2008; 1123: 134–145.
    OpenUrlCrossRefPubMed
  35. ↵
    Hirase T, Staddon JM, Saitou M, Ando-Akatsuka Y, Itoh M, Furuse M, Fujimoto K, Tsukita S, Rubin LL. Occludin as a possible determinant of tight junction permeability in endothelial cells. J Cell Sci. 1997; 110 (pt 14): 1603–1613.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    Bazzoni G. Endothelial tight junctions: permeable barriers of the vessel wall. Thromb Haemost. 2006; 95: 36–42.
    OpenUrlPubMed
  37. ↵
    Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD. Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol. 2006; 1: 223–236.
    OpenUrlCrossRefPubMed
  38. ↵
    Walshe TE, Saint-Geniez M, Maharaj AS, Sekiyama E, Maldonado AE, D'Amore PA. TG. F-β is required for vascular barrier function, endothelial survival and homeostasis of the adult microvasculature. PLoS One. 2009; 4: e5149.
    OpenUrlCrossRefPubMed
  39. ↵
    McCaffrey G, Willis CL, Staatz WD, Nametz N, Quigley CA, Hom S, Lochhead JJ, Davis TP. Occludin oligomeric assemblies at tight junctions of the blood-brain barrier are altered by hypoxia and reoxygenation stress. J Neurochem. 2009; 110: 58–71.
    OpenUrlCrossRefPubMed
  40. ↵
    Wang W, Dentler WL, Borchardt RT. VEGF increases BMEC monolayer permeability by affecting occludin expression and tight junction assembly. Am J Physiol Heart Circ Physiol. 2001; 280: H434–H440.
    OpenUrlAbstract/FREE Full Text
  41. ↵
    Hamik A, Lin Z, Kumar A, Balcells M, Sinha S, Katz J, Feinberg MW, Gerzsten RE, Edelman ER, Jain MK. Kruppel-like factor 4 regulates endothelial inflammation. J Biol Chem. 2007; 282: 13769–13779.
    OpenUrlAbstract/FREE Full Text
  42. ↵
    Segre JA, Bauer C, Fuchs E. Klf4 is a transcription factor required for establishing the barrier function of the skin. Nat Genet. 1999; 22: 356–360.
    OpenUrlCrossRefPubMed
  43. ↵
    Patel S, Xi ZF, Seo EY, McGaughey D, Segre JA. Klf4 and corticosteroids activate an overlapping set of transcriptional targets to accelerate in utero epidermal barrier acquisition. Proc Natl Acad Sci U S A. 2006; 103: 18668–18673.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    Jaubert J, Cheng J, Segre JA. Ectopic expression of kruppel like factor 4 (Klf4) accelerates formation of the epidermal permeability barrier. Development. 2003; 130: 2767–2777.
    OpenUrlAbstract/FREE Full Text
  45. ↵
    Atkins GB, Wang Y, Mahabeleshwar GH, Shi H, Gao H, Kawanami D, Natesan V, Lin Z, Simon DI, Jain MK. Hemizygous deficiency of Kruppel-like factor 2 augments experimental atherosclerosis. Circ Res. 2008; 103: 690–693.
    OpenUrlAbstract/FREE Full Text
  46. ↵
    Sen-Banerjee S, Mir S, Lin Z, Hamik A, Atkins GB, Das H, Banerjee P, Kumar A, Jain MK. Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells. Circulation. 2005; 112: 720–726.
    OpenUrlAbstract/FREE Full Text
  47. ↵
    Hiroi T, Deming CB, Zhao H, Hansen BS, Arkenbout EK, Myers TJ, McDevitt MA, Rade JJ. Proteasome inhibitors enhance endothelial thrombomodulin expression via induction of Kruppel-like transcription factors. Arterioscler Thromb Vasc Biol. 2009; 29: 1587–1593.
    OpenUrlAbstract/FREE Full Text
  48. ↵
    Gracia-Sancho J, Villarreal G Jr, Zhang Y, Garcia-Cardena G Activation of SIRT1 by resveratrol induces KLF2 expression conferring an endothelial vasoprotective phenotype. Cardiovasc Res. 85: 514–519.
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Arteriosclerosis, Thrombosis, and Vascular Biology
October 2010, Volume 30, Issue 10
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Supplemental Materials
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    Kruppel-Like Factor 2 Regulates Endothelial Barrier Function
    Zhiyong Lin, Viswanath Natesan, Hong Shi, Fei Dong, Daiji Kawanami, Ganapati H. Mahabeleshwar, G. Brandon Atkins, Lalitha Nayak, Yingjie Cui, James H. Finigan and Mukesh K. Jain
    Arteriosclerosis, Thrombosis, and Vascular Biology. 2010;30:1952-1959, originally published September 15, 2010
    https://doi.org/10.1161/ATVBAHA.110.211474

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Arteriosclerosis, Thrombosis, and Vascular Biology.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Kruppel-Like Factor 2 Regulates Endothelial Barrier Function
    (Your Name) has sent you a message from Arteriosclerosis, Thrombosis, and Vascular Biology
    (Your Name) thought you would like to see the Arteriosclerosis, Thrombosis, and Vascular Biology web site.
  • Share on Social Media
    Kruppel-Like Factor 2 Regulates Endothelial Barrier Function
    Zhiyong Lin, Viswanath Natesan, Hong Shi, Fei Dong, Daiji Kawanami, Ganapati H. Mahabeleshwar, G. Brandon Atkins, Lalitha Nayak, Yingjie Cui, James H. Finigan and Mukesh K. Jain
    Arteriosclerosis, Thrombosis, and Vascular Biology. 2010;30:1952-1959, originally published September 15, 2010
    https://doi.org/10.1161/ATVBAHA.110.211474
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Arteriosclerosis, Thrombosis, and Vascular Biology

  • About ATVB
  • AHA CME
  • Meeting Abstracts
  • Permissions
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Contact the Editorial Office:
email: atvb@atvb.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured